All In Biotech

Drug Trial Radar · NCT03030105

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled, Single-dose, 6-Period Crossover Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Oct 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Jan 2017

Primary completion

May 2017

Study completion Jun 2017

Sponsor

Lead sponsor
Tetra Discovery PartnersIndustry
Sponsor type
Industry
First posted
Jan 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, randomized, double-blind, placebo-controlled, 6-period crossover study to evaluate the effects of BPN14770 10 mg and 50 mg in reversing scopolamine-induced cognitive impairment in healthy volunteers. A positive control, donepezil 10 mg, will be included, and additivity of BPN14770 50 mg to donepezil 10 mg in reversing scopolamine effects will also be evaluated.

Conditions

  • Alzheimer Disease

Interventions

  • BPN14770Drug

    investigational drug

  • BPN14770 placeboDrug

    placebo

  • DonepezilDrug

    comparator

  • Donepezil placeboDrug

    placebo

  • Scopolamine 0.6 MG/MLDrug

    cognition impairment

  • Scopolamine placeboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Groton Maze Learning Test (GMLT)Time frame: 2 hours post-scopolamine s.c. injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Early Phase Services, LLC

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.